-
New Educational Initiative Addresses COVID-19-Associated Pulmonary Aspergillosis (CAPA) and Other COVID-19 Associated Invasive Fungal Infections (CA-IFIs)
New Educational Initiative Addresses COVID-19-Associated Pulmonary Aspergillosis (CAPA) and Other COVID-19 Associated Invasive Fungal Infections (CA-IFIs)
Initiative Launched by Terranova Medica in collaboration with the University of Alabama at Birmingham and the Mycoses Study Group Education & Research Consortium with partial funding from the Centers for Disease Control and Prevention (CFDA No 93.318 Grant # 1NU50CK000564-01- 00)
Colorado Springs, Colorado. April 30, 2021. Terranova Medica, LLC is pleased to announce the launch of the COVID-19–Associated Fungal Infections Educational Initiative (covidandfungus.org), an educational initiative in collaboration with the the University of Alabama at Birmingham (UAB); the Mycoses Study Group Education & Research Consortium (MSGERC); and funded in part by the Centers for Disease Control and Prevention (CFDA No 93.318 Grant # 1 NU50CK000564-01- 00). The goal of the initiative is to educate clinicians to recognize the risk for IFIs in patients with COVID-19 and appropriately diagnose and treat those IFIs when they occur.
Patients with COVID-19 who require mechanical ventilation are at increased risk for developing COVID-19-associated pulmonary aspergillosis (CAPA) or other COVID-19-associated invasive fungal infections (CA-IFIs). These IFIs are associated with substantial morbidity and mortality. Certain patient groups—including medically underserved populations—are overrepresented in the mechanically ventilated population and thus are particularly vulnerable to these fungal infections.
Healthcare providers and patients can learn more at covidandfungus.org.
About Terranova Medica
Terranova Medica, LLC, is a medical education company whose mission is to deliver high-quality educational initiatives to meet the needs of the healthcare professional and patients, with a special emphasis on interactive e-learning in oncology, infectious diseases, and multiple sclerosis. Since 2010, Terranova has successfully launched dozens of activities on invasive fungal infections in collaboration with the MSGERC. In addition, Terranova has spearheaded multiple oncology-focused initiatives in collaboration with advocacy organizations addressing supportive care issues (such as management of infectious complications), including themelanomanurse.org, aimwithimmunotherapy.org, and skincancerinfo.org.
About the University of Alabama at Birmingham
UAB is a comprehensive urban university with a nationally recognized academic health center. UAB is the only public, four-year degree granting university in the state’s largest metropolitan area. UAB is the largest research institution in the state of Alabama and is the largest single employer in the state.
About the Mycoses Study Group Education & Research Consortium
The MSGERC is a 501c non-profit organization dedicated to providing continuing medical education and scientific/medical thought leadership for evidence-based medicine in the diagnoses, prevention, treatment and maintenance of patients at risk for or afflicted with invasive fungal infections. The MSGERC serves as a resource and support for patients and caregivers who are affected by these serious rare diseases. The MSGERC mission includes setting the annual educational and research agendas for mycology and providing top-quality continuing education initiatives to MSG-member institutions and to other institutions and practitioners throughout the United States and globally.
About the the Centers for Disease Control and Prevention
This educational initiative was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (CFDA No 93.318 Grant # 1NU50CK000564-01- 00) to the University of Alabama at Birmingham. The University of Alabama at Birmingham is collaborating with the Mycoses Study Group Education & Research Consortium and Terranova Medica, LLC, on this initiative. The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this resource center do not necessarily represent the policy of CDC or HHS and should not be considered an endorsement by the Federal Government.
Media Contacts:
Tom Davis, 877-276-4523, tdavis@terranovamedica.com